CANARX Executives Charged Over Illegal Prescription Drug Importation Scheme
Federal authorities arrest CANARX treasurer for allegedly smuggling unapproved medications into the United States.
1Federal Charges Against Executives
U.S. authorities have arrested John Thomas Howard, treasurer of the Canadian company CANARX, on charges of smuggling and conspiracy. His brother, Bob Howard, who serves as the company president, is also wanted in the federal investigation. The charges stem from an alleged long-running scheme to import prescription drugs into the United States illegally.
2Alternative Funding Program Model
CANARX operates as an alternative funding program, or AFP, designed to provide high-cost specialty drugs at lower prices. These companies often bypass traditional supply chains by shipping medications directly from overseas to patients. Employers frequently mandate the use of these programs to reduce healthcare costs, despite warnings regarding potential safety risks.
3FDA Regulatory Scrutiny History
The FDA has investigated CANARX for several years, citing concerns over unapproved and potentially misbranded medications. In 2019, the agency issued a warning letter regarding the substitution of FDA-approved drugs. By 2023, the FDA seized shipments from the company, alleging that the products were counterfeit or did not meet domestic safety standards.
4Legal Defense and Denials
General counsel Joseph Morris stated that the Howard brothers deny all charges and intend to defend themselves vigorously in court. The company maintains that it sources medications from highly regulated countries like Canada, Australia, and the United Kingdom. They argue that their operations are legal and provide necessary access to affordable medicine.
5Civil Litigation and Gilead
Beyond federal criminal charges, CANARX faces a pending civil lawsuit from Gilead Sciences. The pharmaceutical giant accuses the company of illegally importing Biktarvy, a medication used to treat HIV. Gilead claims these actions threaten the integrity of the U.S. medicine supply chain and has publicly supported government efforts to hold the executives accountable.
6The Legality of Importation
The core conflict involves the legality of importing prescription drugs for personal use. While the FDA permits limited importation when drugs are unavailable domestically, officials maintain that using foreign sources as substitutes for FDA-approved medications is generally prohibited. This regulatory gray area serves as the foundation for the business models used by AFPs.
7Scope of the Investigation
The criminal complaint filed by federal authorities covers a period spanning from February 22, 2017, through April 15, 2026. While the affidavit does not specify which particular medications were illegally imported, it confirms that the FDA found probable cause to believe the company facilitated the importation of drugs into the United States.
8Broader Healthcare Industry Impact
This case highlights the growing tension between rising drug costs and federal safety regulations. As employers seek cheaper alternatives for specialty medications, companies like CANARX have gained significant market penetration. The outcome of this trial will likely set a precedent for how alternative funding programs operate within the U.S. healthcare system moving forward.